ChristopherAndrewStrakaMD

PubMed

• 16 citations
  Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer.
  Abhishek Kumar, Christopher Straka, Patrick T Courtney, Lucas K. Vitzthum, Paul Riviere
  International Journal of Radiation Oncology, Biology, Physics. 2021-04-01
• 1 citations
  Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy
  Lucas K. Vitzthum, Christopher Straka, Reith R Sarkar, Rana R. McKay, J. Michael Randall
  Journal of the National Comprehensive Cancer Network. 2019-12-01
• 10 citations
  Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
  James Ying, Chiachien J. Wang, Jingsheng Yan, Stanley L. Liauw, Christopher Straka
  American Journal of Clinical Oncology. 2017-12-01

Journal Articles

• Improving Patient Safety and Quality in HDR Brachytherapy Using�the FMEA Technique  
  Straka C, Ster R, Scanderberg D, Brown D, Yashar C, Mayadev J, BrachyBlast, American Brachytherapy Society, 1/1/2017
• Early and Multiple PSA Bounces Can Occur Following High Dose Prostate Stereotactic Body Radiation Therapy: Subset Analysis of a Phase I/II Trial  
  Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, ... & Pistenmaa, D, Practical Radiation Oncology, 1/1/2017
• Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer  
  Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kupelian P, Brindle J, Cooley S, Perkins A, Raben D, Xie X, Timmerman R, International Journal of Radiation Oncology Biology Physics, 1/1/2014
• Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months  
  Straka C, Kim DW, Timmerman RD, Pedrosa I, Jacobs C, Brugarolas J, Journal of Clinical Oncology, 1/1/2013
• Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib  
  Jacobs C, Kim DW, Straka C, Timmerman RD, Brugarolas J, Journal of Clinical Oncology, 1/1/2013
• Join now to see all

Abstracts/Posters

• Improving Patient Safety and Quality in HDR Brachytherapy Using�the FMEA Technique
  Straka C, Scanderberg D, Brown D, Yashar C, Mayadev J, Winter Institute of Medical Physics, Breckenridge, CO, 1/26/2018
• Assessment of Interrater Reliability for Comorbidity Indices in Determining Eligibility for Treatment Intensification in Head and Neck Cancer
  Feng CH, Vitzthum L, Sojourner E, Zakeri K, Nguyen C, Straka C, Mell LK, ASTRO annual meeting, San Antonio, TX, 1/21/2018
• Early and multiple PSA bounces can occur following high dose prostate SBRT: Subset analysis of a phase I/II trial
  Straka C, Kim DW, Cho LC, Yan J, Lotan Y, Kavanagh B, Xie X, Raben D, Cooley S, Pistenmaa D, Timmerman R, ASTRO annual meeting, San Francisco, CA, 1/15/2014
• Parameters that predict for high grade rectal toxicity in prostate cancer patients undergoing stereotactic body radiation therapy � analysis of phase I/II study at UT ...
  Straka C, Kim DW, Lotan Y, Pistenmaa D, Xie X, Timmerman R, UT Southwestern School of Medicine, 51st Annual Medical Student Research Forum, Dallas, TX, 1/22/2013
• Loss of tumor suppressor DAB2IP correlates with decreased biochemical recurrence free survival in high risk prostate cancer patients treated with radiation therapy
  Kim DW, Tumati V, Pistenmaa D, Kapur P, Xie X, Hannan R, Jacobs C, Straka C, Hsieh JT, Saha D, ASTRO Annual Meeting, Boston, MA, 1/28/2012
• Join now to see all

Lectures

• Parameters that predict for high grade rectal toxicity in prostate cancer patients undergoing stereotactic body radiation therapy � analysis of phase I/II study at UT ... 
  Dallas, TX - 1/22/2013